Tocilizumab Treatment for Nephrotic Syndrome Due to Amyloidosis in Behcet's Disease

被引：30

作者：

Redondo-Pachon, M. D. ^{[1
]}

Enriquez, R. ^{[1
]}

Sirvent, A. E. ^{[1
]}

Andrada, E. ^{[2
]}

Noguera-Pons, R. ^{[3
]}

Millan, I. ^{[1
]}

Amoros, F. ^{[1
]}

机构：

[1] Hosp Elche, Nephrol Sect, Elche, Spain

[2] Hosp Elche, Pathol Sect, Elche, Spain

[3] Hosp Elche, Rheumatol Sect, Elche, Spain

来源：

RENAL FAILURE | 2013年 / 35卷 / 04期

关键词：

tocilizumab; amyloidosis; Behcet's disease; nephrotic syndrome; interleukin-6 (IL-6);

D O I：

10.3109/0886022X.2013.773913

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Renal involvement is an unusual but significant Behcet's disease (BD) complication and AA amyloidosis appears to be the most common etiology. IL-6 is a pro-inflammatory cytokine with an important role in AA amyloidosis development. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that has emerged as an effective and specific treatment in AA amyloidosis secondary to chronic inflammatory disorders. We report on a patient diagnosed with BD who developed nephrotic syndrome caused by renal AA amyloidosis with an excellent response to TCZ therapy.

引用

页码：547 / 550

页数：4

共 14 条

[11] A Behcet case with renal amyloidosis [J].